ANAPTYSBIO, INC · Drugmakers

ANAB

Low riskNext report: Due any day

View price ↗

The short version

A company still losing money with growing sales. Institutions are adding.

Going well

Sales up 24% in the latest quarter vs a year ago
Sales up 157% last year

Watch out for

Losing money

Money moves

Insiders sold $249K in the last 30 days, all through pre-planned sales
Institutions added 6.7% to their holdings in the quarter ending June 2026 (116 bought, 101 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$48.76-0.0% that day

Company value: $1.5B; Share price times all shares
Price vs profit (P/E): 8.5x; You pay about $8 for each $1 of yearly profit
Price vs sales: 6.1x; Company value is 6.1 times a year of sales
Cash vs value: 9%; Cash as a share of company value

From ANAB's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26 (worked out from yearly totals)

$27.5M+23% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $237.6M, up 93% from the 12 months before. Over 5 years, sales grew about 26% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of ANAB. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +93% a yearProfit margin50%Last 12 months: 82.4%P/E at the end8xToday: 8.5x. Many steady companies trade at 12x to 25xShare count change+2% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$882M

Profit in 5 years$441M

Price these guesses point to$106.92+119% vs $48.76 todayAbout +17% a year, before dividends

What today's price needs: with a 50% margin and a 8x P/E, sales would have to grow about 11% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/5Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-24.5%
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-5.6%
MissProfitable every yearSteady profits, not one good year.0 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$19.6M
MissShare count not growingNot diluting owners. Falling means buybacks.+7.3% in 3 years

Revenue: $234.6M; +157.0% vs prior year
5-year growth: +25.6%/yr; revenue, per year
Current ratio: 9.07x; short-term assets / bills due
Free cash flow: $19.6M; 8.4% of revenue

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: debt under half of equity, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported May 12

Revenue: $27.5M; +23.5% YoY
EPS: $5.34; vs -$1.34
Op. margin: 243.6%; +361.1 pts
Free cash flow: -$26.6M

Some values are worked out from year-to-date totals in the annual report.

Insider rating

Last 90 days

47Mixed

Pre-planned sales of $249K (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 0.8
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+6.7%

Institutions added 6.7% to their holdings. 116 bought, 101 sold.

Shares held by institutions30.1M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+4.2%

Cash runwayAt last year's cash burn

Cash flow positive

Shares outstandingLatest reported

30M

Why low risk

Losing money

Earnings reports

Last 12

Next reportDue any dayEstimated from the same quarter last year

Results filedMay 12
Results filedMar 3
Results filedJan 9
Results filedNov 4, 2025
Results filedAug 6, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (passive)Aug 14 · View filing ↗Big holder

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$249K1 insider, 1 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Hollings RentonDirector	Sell	5K	$49.87	$249K	11K	Oct 1Filing ↗
-31.3% of their holdings Pre-planned sale (10b5-1) Filed 1 day after

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

SoldHollings RentonDirector

5,000 shares at $49.87 · $249K

-31% of holdings
Now owns 10,995 shares
Pre-planned sale (10b5-1)
Filed 1 day after trade
Also: Option exercise

Oct 1Form 4 ↗

Planned insider saleOct 1 · Form 144 ↗Current reportSep 21 · Form 8-K ↗10-KTSep 21 · Form 10-KT ↗

Option exerciseJohn A OrwinDirector

1,300 shares

+8% of holdings
Now owns 17,995 shares
Filed 2 days after trade

Sep 15Form 4 ↗

5%+ holder update (passive)Aug 14 · Form SCHEDULE 13G/A ↗Shareholder vote resultsAug 11 · Form 8-K ↗

Stock awardDaniel FagaPresident, CEO, Director

53,334 shares

Now owns 53,334 shares
Performance Stock Units
Filed 148 days after trade

Mar 12Form 4 ↗

Stock awardPaul F. LizzulChief Medical Officer

16,667 shares

Now owns 16,667 shares
Performance Stock Units
Filed 148 days after trade

Mar 12Form 4 ↗

Investor disclosureJul 30 · Form 8-K ↗Planned insider saleJul 13 · Form 144 ↗Planned insider saleJun 30 · Form 144 ↗Proxy statementJun 29 · Form DEF 14A ↗DEFA14AJun 29 · Form DEFA14A ↗ARSJun 29 · Form ARS ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page